IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v18y2021i9p4623-d544182.html
   My bibliography  Save this article

Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013–2017

Author

Listed:
  • Sherali Massavirov

    (Department of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan)

  • Kristina Akopyan

    (WHO Regional Office for Europe, DK-2100 Copenhagen, Denmark
    Tuberculosis Research and Prevention Center NGO, Yerevan 0070, Armenia)

  • Fazlkhan Abdugapparov

    (Department of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan)

  • Ana Ciobanu

    (WHO Regional Office for Europe, DK-2100 Copenhagen, Denmark)

  • Arax Hovhanessyan

    (WHO Regional Office for Europe, DK-2100 Copenhagen, Denmark)

  • Mavluda Khodjaeva

    (Department of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan)

  • Jamshid Gadoev

    (World Health Organization Country Office in Uzbekistan, 16, Tarobiy Street, Tashkent 100100, Uzbekistan)

  • Nargiza Parpieva

    (Department of Phthisiology and Pulmonology of the Tashkent Medical Academy, Tashkent 100109, Uzbekistan
    The Republican Specialized Scientific-Practical Medical Center of Phthisiology and Pulmonology, Tashkent 100086, Uzbekistan)

Abstract

Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection poses a growing clinical challenge. People living with HIV have a higher chance of developing TB, and once the disease has progressed, are at greater risk of having unfavorable TB treatment outcomes. Data on TB treatment outcomes among the HIV-associated TB population in Uzbekistan are limited. Thus, we conducted a cohort study among 808 adult patients with HIV-associated TB registered at the Tashkent TB referral hospital from 2013–2017 to document baseline characteristics and evaluate risk factors for unfavorable TB treatment outcomes. The data were collected from medical records and ambulatory cards. About 79.8% of the study population had favorable treatment outcomes. Antiretroviral therapy (ART) coverage at the admission was 26.9%. Information on CD4-cell counts and viral loads were largely missing. Having extrapulmonary TB (aOR 2.21, 95% CI: 1.38–3.53, p = 0.001), positive sputum smear laboratory results on admission (aOR 1.62, 95% CI: 1.07–2.40), diabetes (aOR 5.16, 95% CI: 1.77–14.98), and hepatitis C (aOR 1.68, 95% CI: 1.14–2.46) were independent risk factors for developing unfavorable TB treatment outcomes. The study findings provide evidence for targeted clinical management in co-infected patients with risk factors. Strengthening the integration of TB/HIV services may improve availability of key data to improve co-infection management.

Suggested Citation

  • Sherali Massavirov & Kristina Akopyan & Fazlkhan Abdugapparov & Ana Ciobanu & Arax Hovhanessyan & Mavluda Khodjaeva & Jamshid Gadoev & Nargiza Parpieva, 2021. "Risk Factors for Unfavorable Treatment Outcomes among the Human Immunodeficiency Virus-Associated Tuberculosis Population in Tashkent City, Uzbekistan: 2013–2017," IJERPH, MDPI, vol. 18(9), pages 1-11, April.
    • Handle: RePEc:gam:jijerp:v:18:y:2021:i:9:p:4623-:d:544182
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/18/9/4623/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/18/9/4623/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Serine Sahakyan & Varduhi Petrosyan & Lusine Abrahamyan, 2020. "Diabetes mellitus and treatment outcomes of pulmonary tuberculosis: a cohort study," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 65(1), pages 37-43, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:9:p:4623-:d:544182. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.